Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial
Jose Luis Vazquez Martinez
-
Source:
Key Points
Question What tobacco smoking cessation rates does psilocybin, an experimental treatment, yield compared with nicotine patch, an established treatment, with individuals in both groups receiving standardized cognitive behavioral therapy?
Findings In this pilot randomized clinical trial, 42 participants randomized to receive psilocybin had more than 6 times greater odds of prolonged smoking abstinence 6 months after treatment than 40 participants who received the nicotine patch.
Meaning These results suggest that psilocybin holds potential in the treatment of tobacco use disorder and, along with other psychedelics, should be investigated further for tobacco and other substance use disorders.
- ISSUP members can join Networks to comment – Sign in or become a member
Según el ensayo clínico aleatorizado piloto publicado en JAMA Network Open (2026), la psilocibina produjo tasas de abandono del tabaquismo considerablemente mayores que el parche de nicotina, cuando ambos grupos recibieron terapia cognitivo-conductual (TCC).
A los 6 meses de seguimiento:
Abstinencia prolongada (resultado principal):
Psilocibina: 40,5%
Parche de nicotina: 10,0%
Abstinencia puntual (7 días):
Psilocibina: 52,4%
Parche de nicotina: 25,0%
Además, los participantes tratados con psilocibina tuvieron más de 6 veces mayor probabilidad de dejar de fumar en comparación con el parche de nicotina.